At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic inventions.
Evolve is a specialist pharmaceutical and biotechnology IP firm. Our team includes scientific experts in chemistry, biochemistry and pharmaceutical science, and we have managed IP strategy for products at every stage of the pipeline, including on-market medicines.
Related technologies: New indications | Formulations | Life cycle management | T cell engagers
Dose inventions are protected differently around the world. In the US they are claimed as methods of treatment, in Europe as second medical uses, and some offices, including China, give dosing features limited weight. We plan dose filings market by market. In Europe, a new dosage regime for a known medicine can be patented in the second medical use format. Dose patents are among the most valuable forms of clinical IP, which is why they are also among the most frequently challenged.
Patent offices often treat finding a safe and effective dose as routine. To succeed, the patent needs to show a surprising technical effect. In T 0792/24, a lower dose of plinabulin that was at least as effective as the higher dose was found inventive. Much of the real innovation in dose selection happens behind the scenes and never appears in regulatory submissions, so it has to be captured deliberately. Mechanistic insights can also support a dose invention.
A study protocol is not the same as a dose invention. In one recent case, a priority document that described a dose-finding protocol without results could not support the later claim to the selected dose, and the priority claim failed. At the same time, the EPO may treat a published trial protocol as giving a reasonable expectation of success. Filing strategy has to balance both risks.
Step-up dosing, dosing intervals, premedication and the route of administration can all support claims. In T 0295/22, the Board of Appeal accepted that a mode of administration can be a new medical use, but the unexpected effects relied on were not enough for inventive step.
Post-published data can support inventive step, but it can also undermine a claim. Phase III results that cast doubt on the claimed effect have sunk a second medical use patent supported by phase II data.
Our fractional IP counsel model places a named senior patent attorney inside your team as your head of IP, working with your clinical team to capture dose innovation as it happens and to time filings around trials and regulatory submissions.
Why fractional IP counsel for dosing inventions? The innovation behind a dose is often hidden in clinical meetings and never reaches the regulatory file. A fractional head of IP from Evolve sits in those meetings, bringing the real-world industry experience that you only get working in-house to capturing dose inventions and timing filings around trials. Our team and AI tools, including the case law bank behind Popper, support them in a way no lone consultant can and few traditional IP firms do, with a global strategic approach.
Popper, our prosecution agent, carries our case law bank on the evidence needed for clinical inventions, and Albert sets out the data behind competitor dose patents so that we can assess their strength quickly. Our attorneys still make every judgement call. Read more about Evolve AI.
In the US and Europe, yes, as a method of treatment in the US and as a second medical use in Europe, if the dose is new and has a surprising technical effect over the prior art, supported by data. Read more: EPO pharma case law trends 2025: Clinical inventions
Usually, because the dose forms part of the label. That is why dose patents can be so valuable, and why they are so often challenged.
When you have data showing the effect of the selected dose. Filing on a protocol alone risks losing priority, and waiting too long risks your own disclosures becoming prior art. Read more: A study protocol is not the same invention
It can support inventive step if the effect was already credible from the application as filed. It cannot fill a gap in the application, and it can also be used against you. Read more: Phase III results sink a second medical use patent
We are happy to have an informal conversation about your programme, with no obligation. You can read more about our team, and we also write a regular newsletter on pharma and biotech IP.